Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.

Mir, O; Watson, S; Massard, C; Le Cesne, A; Benhadji, K A; Soria, J C

Mir, O; Watson, S; Massard, C; Le Cesne, A; Benhadji, K A; Soria, J C.

Afiliação

Mir O; Gustave Roussy Cancer Institute, Sarcoma Group, Villejuif, France. Electronic address: olivier.mir@gustaveroussy.fr.
Watson S; Gustave Roussy Cancer Institute, Department of Drug Development (DITEP), University Paris Saclay, Villejuif, France.
Massard C; Gustave Roussy Cancer Institute, Department of Drug Development (DITEP), University Paris Saclay, Villejuif, France.
Le Cesne A; Gustave Roussy Cancer Institute, Sarcoma Group, Villejuif, France.
Benhadji KA; Eli Lilly and Company, New York, USA.
Soria JC; Gustave Roussy Cancer Institute, Department of Drug Development (DITEP), University Paris Saclay, Villejuif, France.

Ann Oncol ; 31(12): 1782-1784, 2020 12.

Article em En | MEDLINE | ID: mdl-32941988

Assuntos

Benzazepinas; Sarcoma; Humanos; Indazóis; Pirimidinas; Sarcoma/tratamento farmacológico; Sulfonamidas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Benzazepinas Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google